Search
  • MirZyme

MirZyme Therapeutics partners with King Abdulaziz University


MirZyme Therapeutics partners with King Abdulaziz University to accelerate the development of targeted therapeutics using artificial intelligence-assisted diagnostics

  • Research and collaboration to accelerate product development to prevent preeclampsia and other disorders of unmet medical need

  • Foster training of students and researchers in Translational Medicine within the King Abdulaziz University-University of Oxford (KAU-Oxford) Innovation Centre for Artificial Intelligence in Precision Medicine

  • Promote Anglo-Saudi long-term strategic partnership in line with Vision2030 and undertake joint-innovations

Birmingham, November 16, 2020 MirZyme is teaming up with King Abdulaziz University (KAU) to bring its expertise in maternal health and translational medicine to help drive new innovative product development with the KAU-Oxford Centre of Artificial Intelligence of Precision Medicines (CAIPM). The memorandum of agreement is signed virtually in the presence of His Excellency Professor Abdulrahman Al-Youbi, the President of King Abdulaziz University and Professor Asif Ahmed, the Executive Chairman and CEO of MirZyme Therapeutics in United Kingdom.


Dr. Hani Choudhry, Associate Professor of Genomics and Director of CAIPM will lead the KAU partnership. Dr Faisal Alhorairi is the lead for MirZyme in the MENA region. This collaboration will initially focus on the developing a cloud-based AI assisted diagnostic tool that will enable patients and doctors to utilise an app to predict preeclampsia. This will be developed as part of a partnership using MirZyme patented technology. The scientists at KAU-Oxford Innovation Centre will work with scientists at MirZyme to use the real world data collected and analysed by AI from to improve the predictive algorithm for better patient outcome.


H.E. Professor Abdulrahman Obaid Al-Youbi

“KAU is proud to partner with MirZyme in what promises to be an exciting advancement in healthcare and entrepreneurship in science. This partnership will accelerate the development of novel targeted therapeutics with AI-assisted companion diagnostics that are safe, effective and easily accessible to a global patient population. This supports our aspiration to be at the forefront of AI and healthcare innovation”.


Dr Hani Choudhry, Associate Professor and Director of the Oxford-KAU Innovation Centre for Artificial Intelligence in Precision Medicine said, “We are thrilled to establish the collaboration with MirZyme and look forward to utilising AI technologies in the discovery of innovative medicines and diagnostic tool.”


Professor Asif Ahmed Executive Chairman and CEO of MirZyme Therapeutics said, “MirZyme’s vision is to make preeclampsia history. Today, we move a step closer with this unique partnership with the Kingdom of Saudi Arabia. Formalisation of KAU-MirZyme partnership is to promote a greater scientific focus in rapidly moving new molecules to the marketplace that will benefit patients. This we will do using our patented technology in drug discovery combined with AI-assisted diagnostics”.


For further information contact:


Miss May Razei MSc,

Executive Communication Officer,

MirZyme Therapeutic, United Kingdom

Email: May@mirzyme.com


Note for Editors:


  • King Abdulaziz University (KAU) is a public university in Jeddah, Saudi Arabia. In 2021, Times Higher Education ranked it number one university in the MENA region. KAU has been placed in the top 200 universities in the world by four major ranking tables. It was established in 1967 by a decision of the Council Ministers of Saudi Arabia under King Faisal's orders.

  • MirZyme Therapeutics is an innovative early stage biopharmaceutical company focused on the development and commercialisation of targeted therapeutics with companion diagnostics to prevent preeclampsia and fetal growth restriction in pregnancy. The company has been granted global patents for new drugs that prevent preeclampsia. From a business perspective, MirZyme has the ‘potential to generate substantial revenues at impressive rates of growth’. It is the first of its kind in the maternal drug space that has companion diagnostic to accompany its innovative drugs.


134 views0 comments